CROSS-INDUSTRY
Organizations

A review of RDD® Europe 2023 and look ahead to RDD 2024

The Organizers of the Respiratory Drug Delivery Conference Series

Respiratory Drug Delivery (RDD®) Europe 2023 (www.rddonline.com/rddeurope2023) was a memorable conference for the more than 420 delegates who assembled in Antibes, France this spring. They had traveled from 28 countries to learn and discuss the latest science and technology, so vital to the development of successful inhaled and nasal drug products. The Palais des Congrès Antipolis and the adjacent AC Ambassadeur Hotel, where most delegates stayed, ensured those working in corporate R&D, business development and management had opportunities to network with each other, along with academics, regulators, clinicians and consultants active across all facets of respiratory drug delivery.

Approximately 175 delegates participated for the first time, mingling with RDD regulars who have been attending for more than 30 years. Several "first-timers" expressed surprise at how vibrant and expansive Respiratory Drug Delivery Europe 2023 was. Knowledge Spaces, pioneered during the pandemic and now an established feature of RDD conferences, brought people and organizations with shared interests together, both in the congress center and via the conference website.

Select highlights

- Martin Tobin (University of Leicester, UK), the keynote speaker, shared up-to-the-minute analyses implicating genes and pathways influencing pulmonary disease, which provided a great introduction to the Bench to Bedside Knowledge Space.
- Speakers in the Aqueous Agenda: Navigating Nasal, Inspiring Dry Powder Inhalation, and Building a Sustainable Future Knowledge Spaces presented insights on all the major inhalation and nasal platform technologies. Low global warming potential (GWP) propellants and inhaler sustainability was the focus of a lively Explore with Experts session.
- Alternative bioequivalence approaches dominated the Advanced Inhalation: Data Driven Design Knowledge Space, with Will Ganley (Nanopharm) and Bryan Newman (U.S. Food and Drug Administration) sharing their expertise.
- Each of these Knowledge Space program themes carried over to the lively Poster and Exhibition space where 62 companies showcased their innovations alongside 55 posters. One of those posters was presented by Patricia Henriques, a PhD student at the University of Coimbra, Portugal, who was selected as the 2023 VCU RDD Peter R. Byron Graduate Student Award winner for her poster and corresponding paper entitled, "Benchmarking of particle engineering strategies for nasal powder delivery: Characterization of nasal deposition using the Alberta idealized nasal inlet."

Expanded online access

Twelve Workshops, Posters on the Podium and a meeting of the AAPS Inhalation and Nasal Community rounded out a productive and busy conference with more content than could be absorbed in three days. Fortunately, a legacy of the pandemic is that many presentations, posters and workshops were accompanied by on-demand versions that could be viewed by delegates long after the in-person conference ended. In addition, delegates will continue to have access to more than 2,800 peer-reviewed articles in the RDD library, including those from RDD Europe 2023. In fact, during the conference, anyone (not just delegates) had access to online Company Profiles from Exhibitors, Workshop Presenters, and Conference Supporters whose financial generosity made it possible to deliver the program described above.

Sincere thanks

Food and drinks were served from various locations for lunches and breaks to encourage interactions among attendees. Informal networking continued during the gala dinner at the beautiful Bastide du Roy, with unexplained sculptures of giant blue snails in an adjacent field sparking many conversations.

Our sincere thanks to all delegates, sponsors, media partners, reviewers, moderators and helpers at RDD Europe 2023. We look forward to seeing you all again at RDD 2024.

RDD 2024: What to expect and how to participate

Respiratory Drug Delivery (RDD) 2024 will be held at the JW Marriott Starr Pass, Tucson, Arizona, United States, May 5-9, 2024. Starting with an opening reception, the conference will have all the features described above in a longer, four-day format, allowing more in-depth presentations, deeper discussion of pioneering science and additional opportunities for networking in a collegial and business-friendly resort setting.

Preliminary Knowledge Spaces

Initial program topics include New Targets & Treatments, Formulation & Device Innovation, Manufacturing & Industrialization, Nasal Delivery, Regulatory Science, Advanced Data Analytics, Connectivity and Sustainability. These will evolve into podium sessions as speakers are invited.

Deadlines and details

Features and action items to participate in RDD 2024 are listed here. More details and submission links are available at www.rddonline.com/rdd2024.

- Delegate registration now open.
- Two-day integrated Poster and Exhibition Sessions covering all aspects of inhaled and nasal pharmaceuticals. Poster abstract submission deadline: January 22, 2024.
- Exhibit Tables and online Company Profiles highlighting resources, solutions and connections. Exhibitor sign-up now open.
- Delegate-Selectable Workshops providing practical and interactive demonstrations of innovative technologies, products and services.
- The Charles G. Thiel Award, given to a scientist who has pioneered significant developments in the area of respiratory drug delivery. Nomination deadline: November 30, 2023.
- The VCU RDD Peter R. Byron Graduate Student Award. Eligibility is automatic upon acceptance of a qualifying poster abstract.
- Exhibitors, Workshop Presenters and Conference Supporters should sign up now to enjoy maximum Company Profile visibility on the conference website before the conference opens.

We invite all members of the pulmonary and nasal pharmaceutical community to come together at this prestigious conference in Arizona next May.